Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06444815 | A Study of VET3-TGI in Patients With Solid Tumors(STEALTH-001) | recruiting | Phase 1 | 60 | KaliVir ImmunotherapeuticsINDUSTRY | 1 | Apr 7, 2026 | clinicaltrials |
| NCT05170334 | Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma | active not recruiting | Phase 2 | 7 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05703269 | Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy(HYPOGRYPHE) | active not recruiting | N/A | 58 | Wake Forest University Health SciencesOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT06566092 | Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants | active not recruiting | Phase 1 | 40 | Iovance Biotherapeutics, Inc.INDUSTRY | 1 | Apr 6, 2026 | clinicaltrials |
| NCT07511036 | PROSECCO: A Phase 2, Single Arm, Neoadjuvant Study Evaluating Combination Cemiplimab, Fianlimab, And Ipilimumab In Patients With Surgically Resectable Melanoma | not yet recruiting | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 6, 2026 | clinicaltrials |
| NCT05496686 | Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma | active not recruiting | Phase 1 | 16 | Modulation Therapeutics, Inc.INDUSTRY | 1 | Apr 3, 2026 | clinicaltrials |
| NCT06581406 | A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | recruiting | Phase 2 / Phase 3 | 280 | Replimune, Inc.INDUSTRY | 3 | Apr 2, 2026 | clinicaltrials |
| NCT06295159 | Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma | recruiting | Phase 2 | 90 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT05130177 | Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma | active not recruiting | Phase 2 | 8 | Diwakar DavarOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07276386 | Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma | recruiting | Phase 2 | 18 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT07501104 | Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma(TRIUMPH-AM) | not yet recruiting | Phase 2 | 30 | Shanghai Zhongshan HospitalOTHER | 0 | Mar 30, 2026 | clinicaltrials |
| NCT07349940 | Early Detection of Skin Tumors Using a Telemedicine Tool in Primary Care(MEL) | recruiting | N/A | 1,440 | Institute of Health Information and Statistics of the Czech RepublicOTHER_GOV | 1 | Mar 27, 2026 | clinicaltrials |
| NCT04930783 | NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma | active not recruiting | Phase 1 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06008977 | Exercise to Boost Response to Checkpoint Blockade Immunotherapy(EX-BOOST) | active not recruiting | N/A | 12 | AdventHealth Translational Research InstituteOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT07492121 | Screening for Brain Metastases(GAPIMET) | not yet recruiting | Phase 2 | 180 | University of ZurichOTHER | 1 | Mar 25, 2026 | clinicaltrials |
| NCT06075589 | Psychoeducation for Uveal Melanoma | active not recruiting | N/A | 108 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06550674 | Identification of New Candidate Genes for Hereditary Predisposition to Uveal Melanoma(IGCMU) | recruiting | N/A | 50 | Centre Jean PerrinOTHER | 1 | Mar 19, 2026 | clinicaltrials |
| NCT06708455 | Phase 2b of RAPA-201 Cell Therapy in Post-PD-(L)-1 Melanoma | not yet recruiting | Phase 2 | 65 | Rapa Therapeutics LLCINDUSTRY | 1 | Mar 19, 2026 | clinicaltrials |
| NCT04007744 | Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 36 | Mayo ClinicOTHER | 1 | Mar 18, 2026 | clinicaltrials |
| NCT04119024 | Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors | recruiting | Phase 1 | 18 | Anusha KalbasiOTHER | 1 | Mar 17, 2026 | clinicaltrials |
| NCT06418204 | Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics(COSMIC) | recruiting | — | 2,000 | Wake Forest University Health SciencesOTHER | 2 | Mar 17, 2026 | clinicaltrials |
| NCT07477548 | A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies | not yet recruiting | Phase 2 | 67 | Yonsei UniversityOTHER | 0 | Mar 17, 2026 | clinicaltrials |
| NCT02068586 | Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma | active not recruiting | Phase 2 | 210 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Mar 16, 2026 | clinicaltrials |
| NCT05907954 | (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | active not recruiting | Phase 2 | 160 | IDEAYA BiosciencesINDUSTRY | 7 | Mar 16, 2026 | clinicaltrials |
| NCT07469709 | A Study of Biological, Genetic, and Constitutional Factors and Non-invasive Monitoring to Assess Personal Cancer Risks(PRO-ACTIVE) | recruiting | — | 850 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Mar 13, 2026 | clinicaltrials |
| NCT04417621 | Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma | active not recruiting | Phase 2 | 134 | Novartis PharmaceuticalsINDUSTRY | 12 | Mar 12, 2026 | clinicaltrials |
| NCT07364474 | Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver | recruiting | N/A | 10 | Massachusetts General HospitalOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT06223659 | EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers | recruiting | Phase 2 | 100 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT06771544 | Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma | recruiting | Phase 2 | 14 | University of California, IrvineOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT03999749 | A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma | active not recruiting | Phase 2 | 71 | NYU Langone HealthOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04020809 | Neoadjuvant Atezolizumab in Cutaneous Melanoma | active not recruiting | Phase 1 | 20 | The Methodist Hospital Research InstituteOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT04792463 | Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome | recruiting | — | 500 | Mohamed Abdel-RahmanOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT07448831 | A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.(NeoSenti) | recruiting | Phase 2 | 49 | Universitair Ziekenhuis BrusselOTHER | 1 | Mar 9, 2026 | clinicaltrials |
| NCT02362594 | Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054) | active not recruiting | Phase 3 | 1,019 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 5, 2026 | clinicaltrials |
| NCT06961786 | TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma(TUNINTIL-2) | active not recruiting | Phase 1 | 9 | TILT Biotherapeutics Ltd.INDUSTRY | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07112170 | Consolidative Use of Radiotherapy to Block Oligoprogression in Patients With Metastatic Melanoma(CURB-Melanoma) | recruiting | N/A | 52 | University Health Network, TorontoOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT07442292 | PD-L1 Targeting Peptide Probe for PET Imaging of Solid Tumor | not yet recruiting | — | 40 | Peking University Cancer Hospital & InstituteOTHER | 0 | Mar 5, 2026 | clinicaltrials |
| NCT07449754 | Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma | recruiting | Phase 2 | 45 | Hanmi Pharmaceutical Company LimitedINDUSTRY | 1 | Mar 4, 2026 | clinicaltrials |
| NCT04091750 | Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma | active not recruiting | Phase 2 | 14 | Georgetown UniversityOTHER | 1 | Mar 3, 2026 | clinicaltrials |
| NCT02721459 | XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma | active not recruiting | Phase 1 | 26 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 2, 2026 | clinicaltrials |
| NCT06956690 | A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors | recruiting | Phase 1 / Phase 2 | 180 | Hummingbird BioscienceINDUSTRY | 2 | Mar 2, 2026 | clinicaltrials |
| NCT05869539 | ACT-TIL and ANV419 for Advanced Melanoma.(BaseTIL-03M) | active not recruiting | Phase 1 | 10 | University Hospital, Basel, SwitzerlandOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT06346067 | A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | active not recruiting | Phase 3 | 78 | Erasca, Inc.INDUSTRY | 9 | Feb 27, 2026 | clinicaltrials |
| NCT07225036 | Promoting Immunotherapy Efficacy With Low-Dose Liver RT(PRIME-LRT) | recruiting | N/A | 21 | Jordan KharofaOTHER | 1 | Feb 27, 2026 | clinicaltrials |
| NCT07437300 | Influence of a High-fiber Diet on the Microbiota and the Response to Immunotherapy in Patients Treated for Melanoma.(FIBIOME) | not yet recruiting | — | 60 | University Hospital, GrenobleOTHER | 0 | Feb 27, 2026 | clinicaltrials |
| NCT05549297 | Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | recruiting | Phase 3 | 540 | Immunocore LtdINDUSTRY | 12 | Feb 25, 2026 | clinicaltrials |
| NCT06112314 | IMC-F106C Regimen Versus Nivolumab Regimens in Previously Untreated Advanced Melanoma (PRISM-MEL-301)(PRISM-MEL-301) | recruiting | Phase 3 | 680 | Immunocore LtdINDUSTRY | 26 | Feb 25, 2026 | clinicaltrials |
| NCT07428252 | Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma | active not recruiting | N/A | 150 | Institute of Oncology LjubljanaOTHER | 1 | Feb 25, 2026 | clinicaltrials |
| NCT05176470 | Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients | active not recruiting | Phase 1 | 2 | Richard WuOTHER | 1 | Feb 24, 2026 | clinicaltrials |
| NCT06627244 | Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma | recruiting | Phase 2 | 30 | University of MiamiOTHER | 1 | Feb 23, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Apr 7, 2026source: clinicaltrials